Concomitant anti-tumor necrosis factor and anti-interleukin 17 therapy in severe, refractory hidradenitis suppurativa: A case series.

Remicade (infliximab) - J&J

Humira (adalimumab) - AbbVie

Cosentyx (secukinumab) - Novartis

Concomitant anti-tumor necrosis factor and anti-interleukin 17 therapy in severe, refractory hidradenitis suppurativa: A case series. (PubMed, JAAD Int) - Oct 7, 2026 - No abstract available
Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • IL17A • TNFA

http://www.ncbi.nlm.nih.gov/pubmed/42835218

Erin H Amerson; Estella Bastian; Haley B Naik; Lia Bizuneh

Oct 7, 2026